Evidence map›Paper›PMID 29230865›Full record

ReviewJournal of neuroscience research2019

Glial source of nitric oxide in epileptogenesis: A target for disease modification in epilepsy.

Shaunik Sharma, Sreekanth Puttachary, Thimmasettappa Thippeswamy

Abstract readReview
In one paragraph

Review in Journal of neuroscience research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Effects of Phenosanic Acid in Rat Seizure Models.International journal of molecular sciences · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Shaunik SharmaEpilepsy Research Laboratory, Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa.ORCID 0000-0002-3352-6397
Sreekanth PuttacharyCollege of Veterinary Medicine, Oregon State University, Corvallis, Oregon.
Thimmasettappa ThippeswamyEpilepsy Research Laboratory, Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa.ORCID 0000-0002-9326-1896
Iowa State University · USOregon State University · US

Funding

Toxin-specific and symptomatic drugs in combination with novel neuroprotectants effectively counteract DFP-induced long-term neurotoxicityR21NS099007 · NINDS · IOWA STATE UNIVERSITY · PI THIPPESWAMY, THIMMASETTAPPA · 2017 to 2018
$396k
NINDS NIH HHS R21 NS099007
6 · The paper itself

Abstract

Epileptogenesis is the process of developing an epileptic condition and/or its progression once it is established. The molecules that initiate, promote, and propagate remarkable changes in the brain during epileptogenesis are emerging as targets for prevention/treatment of epilepsy. Epileptogenesis is a continuous process that follows immediately after status epilepticus (SE) in animal models of acquired temporal lobe epilepsy (TLE). Both SE and epileptogenesis are potential therapeutic targets for the discovery of anticonvulsants and antiepileptogenic or disease-modifying agents. For translational studies, SE targets are appropriate for screening anticonvulsive drugs prior to their advancement as therapeutic agents, while targets of epileptogenesis are relevant for identification and development of therapeutic agents that can either prevent or modify the disease or its onset. The acute seizure models do not reveal antiepileptogenic properties of anticonvulsive drugs. This review highlights the important components of epileptogenesis and the long-term impact of intervening one of these components, nitric oxide (NO), in rat and mouse kainate models of TLE. NO is a putative pleotropic gaseous neurotransmitter and an important contributor of nitro-oxidative stress that coexists with neuroinflammation and epileptogenesis. The long-term impact of inhibiting the glial source of NO during early epileptogenesis in the rat model of TLE is reviewed. The importance of sex as a biological variable in disease modification strategies in epilepsy is also briefly discussed.

Indexed as

AnimalsBrainDisease Models, AnimalEpilepsyHumansNeurogliaNeuronsNitric OxideNitric Oxide Synthase Type INitric OxideNitric Oxide Synthase Type Iantiepileptogenickainateneuroinflammationnitro-oxidative stressstatus epilepticustemporal lobe epilepsy

Identifiers

PMID29230865
PMCPMC6035106
OpenAlexW2771796541

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.